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Background and purpose: The role of clinical factors, cerebral infarcts and
hippocampal damage in vascular cognitive impairment (VCI) subtypes remains
unclear.
Methods: Non-demented patients with carotid stenosis and recent transient
ischemic attack/stroke had cognitive assessment and brain magnetic resonance
imaging (MRI). Amnestic VCI was deﬁned as memory impairment; non-
amnestic VCI was any other subdomain impairment. Associations of MRI
metrics [log-transformed total ischemic lesion load (log TILL), mesiotemporal
atrophy (MTA) score, hippocampal mean diﬀusivity (hipMD)] with cognitive
performance were assessed.
Results: A hundred and eight patients, 47 with amnestic VCI and 21 with
non-amnestic VCI, were assessed. A higher MTA (odds ratio 12.89,
P = 0.001) and left hipMD (odds ratio 4.43, P = 0.003) contributed to amnes-
tic VCI versus normal. Age-adjusted fluency correlated with log TILL
(P = 0.002). Age-adjusted memory was associated with left hipMD
(P = 0.001), MTA (P < 0.001) but not log TILL (P = 0.14). Left hipMD,
MTA and smoking showed classiﬁcation potential between amnestic VCI ver-
sus normal (area 0.859, P < 0.001).
Conclusions: Neuroimaging assists stratiﬁcation in amnestic VCI character-
ized by hippocampal changes and in non-amnestic VCI by higher ischemic
burden. MTA and hippocampal diﬀusivity show diagnostic biomarker
potential.
Introduction
Vascular cognitive impairment (VCI) is the second
most common cause of acquired dementia and its
prevalence doubles every 5.3 years [1]. VCI is
deﬁned as the spectrum of cognitive impairment
attributable to cerebrovascular causes, ranging from
subtle deﬁcits to dementia [2] and characterized by
various clinical presentations, multiple imaging and
heterogeneous pathologies [3]. Four VCI subtypes
including amnestic, amnestic plus other domains,
non-amnestic single domain, and non-amnestic mul-
tiple domains are described [3]. The current criteria
are used for all forms of cognitive disorders associ-
ated with cerebrovascular disease including car-
dioembolic, atherosclerotic, ischemic, hemorrhagic
or genetic, regardless of the pathogenesis [3]. The
criteria feature a range of vascular and cognitive
pathologies rather than a validated diagnostic entity
[4]. Moreover, they do not categorically deﬁne
standardized radiological evidence of cerebrovascu-
lar disease for VCI or its diverse clinical pheno-
types.
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Heterogeneous cerebrovascular pathology including
subcortical white matter disease, volume of ischemic
lesions, but also global and temporal lobe atrophy
are thought to contribute to cognitive impairment
after stroke [5]. Cognitive deﬁcits in early subcorti-
cal VCI characteristically involve executive dysfunc-
tion and reduced processing speed [5] whilst
memory loss is considered to develop later [6,7].
Apart from clinical risk factors, especially advanc-
ing age and vascular risk [8], the presence of cere-
brovascular disease in brain imaging is considered to
account for the degree of cognitive impairment [9].
Substantial ischemic burden [10], lacunes and strategic
infarcts [11], the location of white matter lesions as
well as non-lesional white matter tissue damage have
been shown to contribute to VCI [12]. Nevertheless,
generalized and hippocampal atrophy on MRI may
be as strongly associated with VCI as the extent of
vascular pathology [13]. Increased hippocampal mean
diﬀusivity (MD) is frequently found in individuals
with amnestic mild cognitive impairment (MCI) and
Alzheimer’s disease (AD), which implies sensitivity to
the neurodegenerative processes associated with AD
[14–16]. There is some evidence that ultrastructural
hippocampal damage – as measured by hippocampal
MD – may also be aﬀected in VCI as MD was shown
to be attributed to volumetric and connectivity
changes in the hippocampi and memory loss after ﬁrst
stroke or transient ischemic attack [17]. With regard
to cognitive subtypes, hippocampal atrophy is known
to predict AD in non-amnestic and amnestic MCI but
might not be as sensitive in non-amnestic MCI [18],
and was found to be less pronounced in non-amnestic
versus amnestic MCI [19]. Whether hippocampal vol-
ume or MD is diﬀerentially altered in amnestic and
non-amnestic subtypes in patients with probable VCI
is unknown.
This study was aimed to examine the neuroimaging
correlates of amnestic versus non-amnestic cognitive
impairment in patients with carotid vascular disease
and recent cerebrovascular ischemic event who ful-
ﬁlled the criteria for probable VCI [3]. The associa-
tions of clinical and vascular factors such as age,
carotid stenosis and index cerebrovascular ischemic
events with amnestic versus non-amnestic cognitive
impairment in the cohort were assessed in relation to
ultrastructural integrity and atrophy of hippocampi
and total volume of brain ischemic lesions. It was
hypothesized that, in patients with probable VCI,
memory impairment would be associated with hip-
pocampal pathology, whereas non-memory cognitive
deﬁcits would be related to vascular pathology and
risk factors.
Methods
Study population
The study population was identical to that recently
reported [12] and was co-recruited from the Imaging
in Carotid Artery Disease (ICAD) study [20] for
which patients with a recent non-disabling cerebrovas-
cular event and an ipsilateral carotid artery stenosis of
>30% were included. Participants were identiﬁed from
stroke services clinics or inpatients at Nottingham
University Hospitals NHS Trust between November
2010 and January 2014. Patients who were incompe-
tent to consent or those with MRI contraindications
were excluded. As part of the original protocol for the
ICAD study, clinically indicated planned carotid inter-
vention led to exclusion. Consenting participants were
interviewed and clinically assessed for eligibility for
this cognitive cross-sectional sub-study including MRI
safety, evaluation of cerebrovascular disease, vascular
risk factors, literacy, dexterity and ability to perform
cognitive tools tasks. Non-English speaking, aphasia,
complete blindness and dense dominant-hand paresis
excluded a few patients from cognitive tests. Adden-
brooke’s Cognitive Examination  revised version
(ACE-R) was used due to excellent sensitivities and
speciﬁcities for the diagnosis of cognitive impairment
[21,22]. ACE-R reliably tests episodic memory, which
is a known function of the left hippocampus [23].
Assessments were conducted on the day of MRI by
trained researchers (AAH, RJS). The ACE-R sub-
scales were used to deﬁne amnestic subtypes [22,24]
based on age-speciﬁc cut-oﬀs for memory loss. Non-
amnestic VCI was deﬁned as normal memory function
but impairment in at least one other domain (fluency
≤9 out of 14, attention and orientation ≤17/18, memory
≤18/26 and visuospatial ≤15/16 in those aged
50–59 years; fluency ≤8/14, attention and orientation
≤17/18, memory ≤19/26 and visuospatial ≤14/16 in 60–
69 years; fluency ≤9/14, attention and orientation ≤16/
18, memory ≤17/26 and visuospatial ≤14/16 in those
over 70 years [24]). Since aphasia is likely to bias
results due to the verbal testing procedures of ACE-R
[25], our eligibility criteria excluded aphasic and non-
English participants, and language subdomain correla-
tions were not assessed in this cohort. It should be
noted that the subdomain-speciﬁc cognitive deﬁnitions
are more inclusive than the global cognitive impair-
ment deﬁnition and patients with single domain MCI
may not qualify for global cognitive impairment
according to the ACE-R < 82 deﬁnition.
All participants received secondary preventative
treatment for stroke according to the current
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guidelines and no treatment was withheld or modiﬁed
for the purpose of the study.
All participants provided written informed consent
in accordance with the study protocol approved by
the local ethics committee.
Imaging protocol
The imaging protocol has been previously reported
[12]. In brief, all participants underwent 3 T MRI (Phi-
lips, Eindhoven, Netherlands; Achieva version 3.1.2
software) including whole brain axial diﬀusion tensor
imaging (DTI) (spin echo single-shot diﬀusion weighted
echo planar imaging, b = 1000 s/mm2, 15 directions,
TR 4.2 s, TE 57 ms, FOV 224 9 135 9 224, matrix
112 9 112, 45 slices of 3 mm thickness) and axial ﬂuid
attenuated inversion recovery (FLAIR) (TR/TE/TI
10.5/0.14/2.75 s, FOV 224 9 135 9 192, matrix 224 9
181, 45 slices of 3 mm thickness).
Diﬀusion tensor imaging pre-processing, includ-
ing motion correction, eddy currents, skull strip-
ping and ﬁtting of the DTI data to the diﬀusion
tensor model to compute fractional anisotropy and
mean diﬀusivity maps was performed using the dif-
fusion toolbox of FSL [26]. Standard image recon-
struction and further analysis was performed using
FSL.
Total brain ischemic lesion load (TILL)
The NeuRoi image processing tool [27] was used to
manually (by DM, supervised by DPA) outline all
infarcted and ischemic appearing lesions including
white matter hyperintense lesions, cortical and subcor-
tical chronic infarctions as determined on FLAIR
images and acute lesions deﬁned on diﬀusion weighted
images as previously described [12] (Fig. 1a, b).
Lesion volume was calculated as the sum of individual
lesion areas 9 (slice thickness + slice gap) to give the
TILL which was normalized to brain volume and log
transformed (log TILL). Brain volume was measured
with SIENA, part of the FMRIB software library
[28].
Mesiotemporal atrophy (MTA) scores
For each individual, MTA was assessed on recon-
structed coronal FLAIR images using Scheltens’ scale
[29]. As previously described [12], the presence of
MTA was deﬁned using averaged age-ranged speciﬁc
cut-oﬀs for the mean MTA scores, i.e. MTA >1.5 in
participants <75 years of age, MTA >2 in patients
≥75 years or MTA >2.5 in those ≥85 years of age
[30].
Hippocampal mean diffusivity assessment
In order to avoid partial volume eﬀects from cere-
brospinal ﬂuid (CSF), MD maps were thresholded
using a visually optimized cut-oﬀ retaining only voxels
with MD ≤1.5 9 103 mm2/s [31]. Left and right hip-
pocampal MD were determined by manually drawing
regions of interest (ROIs) on three consecutive images
(size 27 voxels, 216 mm3) (Fig. 1c). The grand average
over all left and right regional hippocampal MD was
calculated to reﬂect hippocampal MD (hipMD) and
separately reported for the left hippocampal MD (left
hipMD). In addition, hippocampal formation was
visually inspected on FLAIR, MD and DWI to assess
the presence or absence of acute/chronic lesions.
Statistical analysis
The study sample size was predetermined in the par-
ent study (ICAD) [20] and a power calculation using
SamplePower 2.0 (SPSS, version 19.0, Chicago, IL,
USA) was performed for amnestic and non-amnestic
cognitive impairment subgroups.
The Student t test, MannWhitney U test and chi-
squared test were used to compare the data. One-way
ANOVA, Tukey’s test and Kruskal–Wallis analyses were
performed in order to examine the associations of
clinical factors as well as neuroimaging markers
between the three groups: vasculopathy with normal
cognition, amnestic VCI and non-amnestic VCI. The
normality of the data was assessed before the analysis
and mention is made whenever the data were not nor-
mally distributed.
Binary univariate analysis was applied to determine
the associations between the factors.
Multivariate logistic forward stepwise regression
analysis was used to study associations of age, smok-
ing, presenting ischemic event, log TILL, MTA scores
and left hipMD between the amnestic and non-amnes-
tic VCI subgroups. To quantify the associations of
neuroimaging markers and clinical risk contributors
to amnestic VCI, estimated probabilities calculated
from multivariate logistic regression models for the
receiver operating characteristic (ROC) curve were
used. The ROC curve model, which is a measure of
discrimination and directly applicable to a classiﬁca-
tion setting [32], was used in order to deﬁne important
clinical risk factors and imaging markers in the classi-
ﬁcation of amnestic VCI.
To probe the independence of MTA scores from
CSF thresholded hipMD, the correlations between
both imaging markers were assessed and the associa-
tions of clinical and imaging factors were independently
tested in the subgroup with normal MTA scores.
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Partial correlation analyses, controlled for age, were
used to assess the contributions of log TILL or left
hipMD to each cognitive subdomain including fluency,
visuospatial, attention and orientation, and memory.
Applying the Bonferroni correction because four
subdomain and four MRI metrics were used, the
results with a P value less than 0.0031 were considered
signiﬁcant.
Statistical analysis was performed using SPSS soft-
ware (version 19.0, Chicago, IL, USA). P < 0.05 was
considered statistically signiﬁcant. Data are reported
as mean  standard deviation unless stated otherwise.
Results
The study has 89% power to detect a correlation of
0.3 for the sample size. There is 80% power to detect
a standardized mean diﬀerence of 0.61 for amnestic
versus normal, 0.77 for non-amnestic versus normal
and 0.75 for amnestic versus non-amnestic subgroups.
General findings and cognitive profile
Of 147 recruited participants eligible for the cognitive
sub-study, 108 [66 men (age 74.3  9.5), 42 women
(age 75.2  8.8)] had good image quality for analysis
(Table 1). Of these, 53 presented with stroke and had
larger volumes of total ischemic lesion compared with
55 patients presenting with transient ischemic attack
(P = 0.03).
Mean total ACE-R score was 81.5  10.5. Sixty-
eight participants (63%) showed MCI in at least one
domain (including 15 not classed as overall cognitive
impairment based on ACE-R >82). In total, 47
(43.5%) subjects showed memory impairment (using
established cut-oﬀ scores [24]), of whom 12 had pure
amnestic and 35 memory plus other cognitive domain
impairment. Twenty-one participants (19.4%) were
classed as non-amnestic cognitive impairment aﬀecting
one domain in 11/21 and multiple domains in 10/21.
Clinical risk factors and neuroimaging findings in
cognitive subgroups
Compared with never-smokers, a history of smok-
ing was associated with amnestic VCI versus nor-
mal cognition (P = 0.014, Table 1). Peripheral
vascular disease and presenting symptoms diﬀered
in the three-group analysis (P = 0.048, P = 0.045,
respectively), but there was no pairwise signiﬁ-
cance. No other clinical factor diﬀered between
the amnestic, non-amnestic and normal cognition
groups (Table 1).
There were no ischemic lesions noted in the hip-
pocampi of the study cohort. Left hipMD was signiﬁ-
cantly higher in amnestic VCI, compared with
cognitively intact subjects [mean diﬀerence 0.359, 95%
conﬁdence interval (CI) 0.112–0.606, SE 0.10398,
P = 0.002] (Fig. 2). Conversely, left hipMD did not
diﬀer between non-amnestic VCI and normal
(a)
(c)
(b)
Figure 1 Manual outlines for volumetry
of (a) acute ischemic lesions on standard
diﬀusion images (DWI) and (b) chronic
ischemia on FLAIR images. (c) Outlines
of hippocampi by drawing ROIs on
CSF-thresholded mean diﬀusivity (MD)
map to derive average hippocampal
MD. [Colour ﬁgure can be viewed at
wileyonlinelibrary.com].
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cognition groups (P = 0.75) with a trend reduction
versus amnestic VCI (mean diﬀerence 0.265,
P = 0.097).
Log TILL showed a trend to be higher in the
amnestic VCI group versus normal cognition (mean
diﬀerence 0.709, 95% CI 0.003–1.421, SE 0.2995,
P = 0.051). However, log TILL did not diﬀer between
the non-amnestic versus normal (P = 0.11) or amnes-
tic (P = 0.99) subgroups.
Amnestic VCI versus vasculopathy with normal
cognition
Univariate regression analysis showed that high
hipMD [odds ratio (OR) 3.75, 95% CI 1.4–10.1;
P = 0.009], high left hipMD (OR 4.43, 95% CI 1.66–
11.83, P = 0.003), abnormal MTA (OR 12.89, 95%
CI 2.77–59.9, P = 0.001) and high log TILL (OR
1.43, 95% CI 1.04–1.95; P = 0.027) were signiﬁcant
factors associated with amnestic VCI but not right
hipMD (P = 0.1). In addition, the only clinical factors
with signiﬁcant associations included presenting with
stroke (OR 2.99, 95% CI 1.25–7.19, P = 0.014) and
smoking (OR 3.82, 95% CI 1.47–9.93, P = 0.006). In
multivariate forward stepwise regression analysis of
clinical and imaging factors, four factors indepen-
dently contributed to amnestic VCI, compared with
normal cognition: abnormal MTA scores (OR 18.48,
95% CI 3.3–103, P = 0.001), left hipMD (OR 4.88,
95% CI 1.57–15.16, P = 0.006), presenting with stroke
(OR 4.44, 95% CI 1.42–13.86, P = 0.01) and smoking
(OR 3.9, 95% CI 1.14–13.4, P = 0.031). The corre-
sponding area under the ROC curve was 0.859 (95%
CI 0.784–0.934; P < 0.001) (Fig. 3).
Given the strong association with MTA and the
potential for including patients with comorbid AD
Table 1 Demographic characteristics and risk factors in participants with normal cognition, amnestic and non-amnestic cognitive impairment
at the time of recruitment into the study
Characteristic
Normal
cognition
(n = 40)
Amnestic
VCI
(n = 47)
Non-amnestic
VCI (n = 21) P
Age, mean years  SD 72.4  8.8 75.5  9.8 77.1  7.6 0.131
Female, n (%) 18 (45%) 13 (27.7%) 11 (52.4%) 0.094
AF 7 (17.5%) 12 (25.5%) 5 (23.8%) 0.65
PVD 3 (7.5%) 12 (25.5%) 2 (9.5%) 0.048b
IHD 12 (30%) 17 (36.2%) 5 (23.8%) 0.57
Hypertension 33 (82.5%) 38 (80%) 17 (81%) 0.98
Non-smoker (versus ex- or current) 10 (25%) 9 (19.1%) 9 (42.9%) 0.014c
Diabetes mellitus 8 (20%) 12 (25.5%) 4 (19%) 0.76
DWI lesions positive 14 (35%) 24 (51%) 8 (38.1%) 0.28
Laterality (left side) 17 (42.5%) 23 (49%) 12(57.1%) 0.54
Presenting symptoma (stroke) 14 (35.5%) 29 (61.7%) 10 (47.6%) 0.045b
Higher education (university/college) 5 (12.5%) 2 (4%) 1 (4.7%) 0.3
Degree of stenosis (ipsilateral to ischemic event), n
30%–49% 21 (52.5%) 20 (42.6%) 9 (42.9%) 0.56
50%–69% 14 (35.5%) 23 (48.9%) 8 (38.1%)
>70% 5 (12.5%) 4 (8.5%) 4 (19%)
Degree of stenosis (contralateral to ischemic event), n
0%–29% 29 (72.5%) 31 (66%) 11 (52.4%) 0.35
30%–49% 5 (12.5%) 3(6.4%) 5 (23.8%)
50%–69% 3 (7.5%) 9 (19.1%) 3 (14.3%)
>70% 3 (7.5%) 4 (8.5%) 2 (9.5%)
Time between presenting symptom and MRI,
mean days  SD
35.8  27 33.5  32.8 37  28.2 0.51d
Hippocampal MD 9 103 mm2/s 0.752  0.047 0.781  0.046 0.754  0.029 0.006c
Left hippocampal MD 9 103 mm2/s 0.746  0.055 0.782  0.045 0.756  0.04 0.003c
TILL mm3  SD (log TILL) 13083  18160
(5.6  1.48)
20188  20622
(4.94  1.136)
19965  21749
(4.89  1.271)
0.022c,d
Presence of MTA 2 (5%) 19 (40%) 2 (9.5%) <0.001c
AF, atrial ﬁbrillation; DWI, diﬀusion weighted imaging; PVD, peripheral vascular disease; IHD, ischemic heart disease; log TILL, logarithmic
normalized total ischemic lesion load; MD, mean diﬀusivity; MRI, magnetic resonance imaging; MTA, mesiotemporal atrophy; VCI, vascular
cognitive impairment.aIndexed cerebrovascular ischemic symptoms at presentation; bno pairwise signiﬁcance; cP < 0.05 and, where P value is
signiﬁcant, it reﬂects normal cognition versus amnestic VCI; all associations were analyzed using ANOVA except when the data were not nor-
mally distributed; dKruskal–Wallis analysis (data not normally distributed).
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pathology, the analysis was repeated in the subgroup
of patients with normal MTA scores (MTA-ve), i.e.
no apparent hippocampal atrophy and hence a low
likelihood of subclinical AD (n = 28/85 amnestic VCI,
n = 38/85 normal cognition). The associations of
bilateral hippocampal ultrastructural damage (OR
3.04, 95% CI 1.03–8.98, P = 0.044) and left hipMD
(OR 3.75, 95% CI 1.32–10.66, P = 0.013) in MTA-ve
amnestic VCI were conﬁrmed.
To further corroborate the independence of hipMD
from macroscopic atrophy scores, the association of
all MTA scores with total and left hipMD was
assessed, which proved non-signiﬁcant (P = 0.08,
P = 0.31, respectively). Furthermore, there was no
relationship in a general linear model between total or
left hipMD and all MTA scores in the normal, amnes-
tic and non-amnestic groups (P = 0.67 and 0.17
respectively).
Non-amnestic probable VCI versus vasculopathy with
normal cognition
Using a univariate regression model, log TILL (OR
1.4, 95% CI 0.99–2.22, P = 0.056) and age (OR 1.08,
95% CI 1.00–1.16, P = 0.051) showed trends for asso-
ciations with non-amnestic VCI compared with the
normal cognition subgroup. There were no signiﬁcant
variables in the multivariate logistic regression analysis.
Amnestic versus non-amnestic probable VCI
In separate binary logistic regression models, entering
a single explanatory variable in each model, amnestic
VCI was only associated with left hipMD (OR 4.31,
95% CI 1.15–16.1, P = 0.031), abnormal MTA scores
(OR 6.45, 95% CI 1.34–30.9, P = 0.02) and smoking
(OR 3.17, 95% CI 1.02–9.79, P = 0.045). Conversely,
neither log TILL (P = 0.88), age (P = 0.44) nor pre-
senting ischemic symptom (P = 0.28) were associated
with amnestic versus non-amnestic VCI. The results
of multivariate forward stepwise regression analysis
showed that only abnormal MTA was a signiﬁcant
Figure 2 Bars to display the group mean
and standard deviations of left (light
grey bars) and bilateral (black bars) hip-
pocampal mean diﬀusivity (MD)
between vasculopathy with normal cog-
nition, amnestic and non-amnestic VCI.
(MD units, 103 mm2/s).
Figure 3 ROC curve with diagonal reference (dotted line) for
associations of amnestic vascular cognitive impairment with hip-
pocampal mean diﬀusivity (hipMD), MTA status (normal/ab-
normal), stroke at presentation and smoking (continuous line)
compared with vasculopathy with normal cognition.
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contributing factor with odds ratio the same as above.
In the subgroup with normal MTA scores (n = 28
amnestic versus n = 19 non-amnestic), left hipMD was
signiﬁcantly associated with amnestic VCI (OR 5.42,
95% CI 1.21–24.24, P = 0.027), compared with the
non-amnestic subgroup.
Neuroimaging findings and subdomain cognitive
performance
Fluency signiﬁcantly correlated with higher log TILL
after adjusting for age (r = 0.3, P = 0.002). Perfor-
mance for visuospatial (r = 0.18, P = 0.058, age cor-
rected) or attention and orientation (r = 0.19,
P = 0.051, age corrected), however, was not signiﬁ-
cantly correlated with log TILL.
Memory decline was associated with higher left
hipMD (r = 0.324, P = 0.001, age corrected) and
higher MTA scores (r = 0.35, P < 0.001, age cor-
rected), which were considered signiﬁcant after Bon-
ferroni correction. However, memory was not
signiﬁcantly associated with log TILL (P = 0.14, age
corrected), presenting with stroke (P = 0.15, age cor-
rected) or smoking (P = 0.009, age corrected). MTA
scores were not signiﬁcantly associated with fluency
(P = 0.018, age corrected) or attention and orientation
(P = 0.005, age corrected).
Discussion
In this study of patients with recently symptomatic
carotid artery disease, distinct association proﬁles for
clinical risk factors and neuroimaging markers of
amnestic and non-amnestic probable VCI have been
described. Ultrastructural left hippocampal damage,
indexed as increased mean diﬀusivity (hipMD), MTA
scores, presence of stroke and smoking habit were sig-
niﬁcant predictors of amnestic VCI. Conversely, older
people were more likely to have non-amnestic VCI,
and higher total ischemic lesion burden showed a ten-
dency to predict non-amnestic VCI. This dissociation
was further conﬁrmed by divergent patterns of corre-
lation with performance in cognitive subdomains:
total ischemic lesion burden was signiﬁcantly corre-
lated with performance in verbal fluency, whilst MTA
scores and hipMD were associated with memory per-
formance.
A predominant eﬀect from hippocampal ultrastruc-
tural damage, particularly the left hippocampus, in
patients with amnestic VCI was shown in our study.
Notably, no evidence was found to suggest that extra-
hippocampal cerebral ischemic lesion load, age or vas-
cular risk factors contributed to memory loss account-
ing for hippocampal damage. Memory function, in
particular long recall and delayed recognition, are
both typically considered as hippocampal-dependent
functions [33]. Whilst the role of the right hippocam-
pus is on allocentric processing of space, the left hip-
pocampus is more involved in context-dependent
episodic memory [23]. Hippocampal damage on diﬀu-
sion MRI and hippocampal atrophy were reported to
predict cognitive impairment after stroke [17]. How-
ever, the relationship between hippocampal atrophy
and especially hippocampal ultrastructural tissue dam-
age and cognitive impairment in VCI has remained
unclear [4]. Although in one study, hipMD after cere-
brovascular ischemic events was thought to precede
hippocampal atrophy and disconnection [17], that
study did not correct for partial volume eﬀects mak-
ing it impossible to exclude atrophy eﬀects. Using
careful ROI selection and CSF thresholding, we have
now shown that the associations of atrophy indexed
as MTA scores and hippocampal tissue damage (atro-
phy corrected MD) with memory loss in VCI are
independent. Although elevated hipMD can be predic-
tive of memory decline in healthy elderly individuals
[34] and prodromal AD [35], there is insuﬃcient evi-
dence to prove that hipMD changes cause hippocam-
pal atrophy. Elevated mean diﬀusivity of the anterior-
dorsal hippocampus was observed in spontaneous
hypertensive rats, a recognized model of VCI even
before behavioural deﬁcits were noted [36]. In our
study, signiﬁcant ischemic lesions in the hippocampi
and parahippocampal regions were excluded by care-
ful review of imaging. It is plausible that high MD,
which indicates a local increase of free water diﬀusiv-
ity in the parenchyma, is linked to reduction in myelin
content, axonal decline or depletion of extracellular
matrix [37].
Mesiotemporal atrophy scores were signiﬁcant pre-
dictors of the amnestic VCI cohort, whereas MTA
scores were not signiﬁcantly impaired in our non-
amnestic subgroup. The MTA score strongly supports
the clinical diagnosis of AD at early stages of the dis-
ease, and it is related to memory dysfunction and
delayed recall [29]. Although our study population rep-
resents VCI, we have shown a subgroup with predomi-
nant memory loss, amnestic VCI, with radiological
evidence of MTA. This amnestic VCI conceivably
might represent a mixed type pre-manifest dementia
with additional pathology of AD. Whilst this remains
speculative without evidence for amyloid pathology
using CSF or positron emission tomography (PET)-
imaging, our ﬁndings are well in line with a previous
report of less severe MTA scores in non-amnestic post-
stroke VCI compared with amnestic subtypes [38].
Neuropsychological studies have shown VCI atten-
tional-executive deﬁcits [39,40] with frequently
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observed subcortical vascular pathology and interrup-
tion in the frontostriatal circuits [41–43]. Similarly, a
trend for associations with fluency impairment and
total ischemic lesion volume as a measure of vascular
pathology was found in our cohort. Further studies
are required to clearly demonstrate the pathways and
mechanisms in non-amnestic VCI; elaboration and
reﬁning lesion and tract injury have been shown to
have diagnostic potential [12]. In our study popula-
tion, ultrastructural hippocampal damage was not
associated with non-amnestic VCI. This proﬁle is fur-
ther supported by the current evidence that cortical
and subcortical infarcts primarily aﬀect non-memory
domains of cognition, mostly executive function
[7,44]. The extent of infarcts tended to play roles in
non-amnestic VCI; likewise, non-amnestic MCI has
been reported to be suggestive of vascular disease and
more infarcts in a small cohort [19]. The associations
between fluency – a non-amnestic subdomain – and
total ischemic burden additionally support primary
vascular pathology in non-amnestic VCI.
Our study does not allow pathological conﬁrma-
tion, but provides radiological evidence for selective
left hippocampal damage in amnestic VCI compared
to the non-amnestic group who showed more cere-
brovascular disease burden. Coexisting preclinical AD
is expected in 11%–20% of people aged 65 and older
[45,46], conﬁrmation of which would have required
availability of amyloid and tau CSF markers or amy-
loid-PET, which our study is lacking. ACE-R cut-oﬀ
scores for detection of subdomain impairment after
stroke have good validity to detect executive, visu-
ospatial and attention impairment but not memory
[24]. Nevertheless, age-adjusted overall memory scores
showed similar results in our study. The third limita-
tion is the cross-sectional design that does not allow
comment on the predictive value of our neuroimaging
ﬁndings to predict the clinically most relevant conver-
sion to vascular dementia. Longitudinal neuroimaging
studies are required to better clarify the natural pro-
gression of VCI subtypes, and to assess the value of
neuroimaging predictors of conversion to diﬀerent
types of dementia.
We describe two distinctive VCI subtypes to replace
the current criteria with a heterogeneous descriptive
entity to allow clinical and imaging stratiﬁcation for
clinical trials and future treatment strategies. It is
plausible that amnestic VCI may represent the sub-
group of VCI closer to Alzheimer’s pathology and
may be selected for pre-manifest Alzheimer’s/mixed
type dementia prevention trials. Moreover, in clinical
trials of VCI, focusing on non-amnestic VCI subtypes
especially with absent MTA may oﬀer a pure VCI
cohort for intervention trials in which subsiding
cerebrovascular pathology is targeted. Conversely, for
treatment trials aiming to prevent further hippocam-
pal pathology, we anticipate potential gain from strat-
iﬁcation in amnestic and non-amnestic VCI with or
without MTA abnormality and characterization using
hippocampal mean diﬀusivity.
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